← Back to Portfolio

SFJ X (PhaseBio)

SFJ X supported a clinical co-development deal with PhaseBio (NASDAQ: PHAS) to fund and manage clinical development of PB2452 which is an antidote to Brilinta, an oral anti-platelet medicine . Reversal of this anti-clotting activity is needed to reduce the risk of bleeding in high risk situations such as trauma or surgery. The phase 3 primary endpoint was positive and the company plans on submitting for FDA approval shortly.